Edaravone
Ingredients
Indication
Used to improve neurological symptoms, daily living activities and functional disorders caused by acute cerebral infarction.
Usage and Dosage
30 mg once, twice a day. Dilute with an appropriate amount of saline and drip intravenously. The drip should be completed within 30 minutes. One course of treatment is within 14 days. Start the medication within 24 hours after the onset of the disease if possible.
Adverse Reactions
Serious adverse reactions include: 1. Acute renal failure (extent unknown). Perform multiple renal function tests and observe closely during medication. If symptoms such as renal dysfunction or oliguria occur, stop medication and handle properly. 2. Abnormal liver function and jaundice (extent unknown). Accompanied by abnormal liver function and jaundice such as increased AST, ALT, ALP, γ-GT, and LDH. Liver function tests and close observation are required during medication. If abnormal conditions occur, stop medication and handle properly. 3. Thrombocytopenia (extent unknown). There are thrombocytopenia symptoms. Close observation is required during medication. If abnormal conditions occur, stop medication and handle properly. 4. Disseminated intravascular coagulation (DIC) (extent unknown). Symptoms of disseminated intravascular coagulation may occur. Test regularly during medication. If laboratory manifestations and clinical symptoms suspected of disseminated intravascular coagulation occur, stop medication and handle properly. Other adverse reactions (incidence) and their main manifestations are: 1. Allergy (0.1%-5%): Mainly manifested as rash, flushing, swelling, herpes, and itching. 2. Blood cell system (0.1%-5%): Mainly manifested as erythropenia, leukocytosis, leukocytosis, hematocrit decrease, hemoglobin decrease, thrombocytosis, and thrombocytopenia. 3. Injection site (0.1%-5%): Mainly manifested as rash and redness and swelling at the injection site. 4. Liver (incidence>5%): Mainly manifested as increased AST, increased ALT, increased LDH, increased ALP, and increased γ-GT. (Incidence 0.1%-5%): Increased total bilirubin, positive urobilinogen, and bilirubinuria. 5. Kidney (0.1%-5%): Mainly manifested as increased BUN, increased serum uric acid, decreased serum uric acid, increased proteinuria, hematuria, and increased creatinine (to unknown extent). 6. Digestive system (0.1%-5%): belching. 7. Others (0.1%-5%): fever, feeling of heat, increased blood pressure, increased serum cholesterol, decreased serum cholesterol, increased triglycerides, decreased serum total protein, increased CK (CPK), decreased CK (CPK), decreased serum potassium, and decreased serum calcium.
Storage
Sealed and moisture-proof
Manufacturer
Lesheng Pharmaceutical Shijiazhuang Co., Ltd.
-
Founded in:
2002-12-10 -
Address:
No. 198, Xiangjiang Road, Shijiazhuang High-tech Zone -
Tax NO.:
9113010180441898XY -
Registered Funds:
830,000 yuan -
Website:
-
Email: